Brief: Kintara Therapeutics Pauses Rem-001 Program
19/10/2022 13:18
Oct 19 (Reuters) - Kintara Therapeutics Inc KTRA.O :
* KINTARA THERAPEUTICS PAUSES REM-001 PROGRAM TO CONSERVE
FUNDS TO
SUPPORT VAL-083 INTERNATIONAL REGISTRATIONAL STUDY
* KINTARA THERAPEUTICS INC - REM-001 15-PATIENT STUDY PAUSED
TO
CONSERVE FUNDS - APPROXIMATELY $3 MILLION SAVED THROUGH 2023
Source text for Eikon: ID:nPn9BJcpTa
Further company coverage: KTRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TuHURA Biosciences
See all newsBrief: Tuhura Biosciences Receives Key U.S. Patent For Its Groundbreaking Delta Opioid Receptor Antibody Drug Conjugate Technology
TuHURA Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tuhura Biosciences Reports Second Quarter 2026 Financial Results And Provides A Corporate Update
TuHURA Biosciences Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co.